Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

Antonio Russo; null Russo; null Toscano; null Sava; null Battaglia; null Raiti; Antonino Scimone; Vincenzo Adamo; Maria Picciotto

Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

Antonio Russo, Russo, Toscano, Sava, Battaglia, Raiti, Antonino Scimone, Vincenzo Adamo, Maria Picciotto

Discipline Chirurgiche, Oncologiche e Stomatologiche

Risultato della ricerca: Article › peer review

Abstract

Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.

Lingua originale	English
pagine (da-a)	vi61-
Numero di pagine	1
Rivista	Annals of Oncology
Volume	28
Stato di pubblicazione	Published - 2017

All Science Journal Classification (ASJC) codes

???subjectarea.asjc.2700.2720???
???subjectarea.asjc.2700.2730???

Altri file e collegamenti

OA Link

Fingerprint

Entra nei temi di ricerca di 'Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis'. Insieme formano una fingerprint unica.

Cita questo

Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis. / Russo, Antonio; Russo; Toscano; Sava; Battaglia; Raiti; Scimone, Antonino; Adamo, Vincenzo; Picciotto, Maria.

In: Annals of Oncology, Vol. 28, 2017, pag. vi61-.

Risultato della ricerca: Article › peer review

Russo, A, Russo, Toscano, Sava, Battaglia, Raiti, Scimone, A, Adamo, V & Picciotto, M 2017, 'Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis', Annals of Oncology, vol. 28, pagg. vi61-.

Russo, Antonio ; Russo ; Toscano ; Sava ; Battaglia ; Raiti ; Scimone, Antonino ; Adamo, Vincenzo ; Picciotto, Maria. / Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis. In: Annals of Oncology. 2017 ; Vol. 28. pagg. vi61-.

@article{4be62c8171804d2e9a7331f26a1dc772,

title = "Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis",

abstract = "Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.",

author = "Antonio Russo and Russo and Toscano and Sava and Battaglia and Raiti and Antonino Scimone and Vincenzo Adamo and Maria Picciotto",

year = "2017",

language = "English",

volume = "28",

pages = "vi61--",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

AU - Russo, Antonio

AU - Russo, null

AU - Toscano, null

AU - Sava, null

AU - Battaglia, null

AU - Raiti, null

AU - Scimone, Antonino

AU - Adamo, Vincenzo

AU - Picciotto, Maria

PY - 2017

Y1 - 2017

N2 - Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.

AB - Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.

UR - http://hdl.handle.net/10447/412779

M3 - Article

VL - 28

SP - vi61-

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -